The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
A major push to sharpen the future of cancer treatment is underway
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
